Parkinson disease

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

Here is a comprehensive overview of Parkinson Disease (PD) drawn from multiple authoritative medical textbooks.

Parkinson Disease

Definition & Epidemiology

PD is the second most common progressive neurodegenerative disorder after Alzheimer disease. It affects approximately 1% of people over age 60 and 4–5% of those over 85. The disease is uncommon before age 40, and incidence is higher in men than women. Up to 15% of patients have a first- or second-degree relative with PD, suggesting genetic predisposition.

Pathophysiology

PD results from loss of dopaminergic neurons in the substantia nigra pars compacta, which project to the striatum (nigrostriatal pathway) and are critical for motor control. The hallmark pathologic finding is the Lewy body — an eosinophilic, round intracytoplasmic inclusion composed of α-synuclein, neurofilaments, and ubiquitin.

Circuit-level mechanism:

Role of the substantia nigra in Parkinson disease — dopamine-acetylcholine imbalance

Normally, substantia nigra neurons release inhibitory dopamine onto neostriatal cholinergic neurons. In PD:

Death of nigral cells → less dopamine release in the neostriatum
Loss of dopaminergic inhibition → relative excess of excitatory acetylcholine
Abnormal motor signaling → impaired voluntary movement

Molecular pathogenesis:

α-synuclein misfolds and aggregates intraneuronally
Defective autophagy and lysosomal degradation (Parkin, LRRK2, glucocerebrosidase mutations)
Mitochondrial dysfunction
Gross pathology: pallor of the substantia nigra and locus ceruleus

Clinical Features

The classic triad (usually asymmetric at onset):

Feature	Description
Tremor	"Pill-rolling" resting tremor; presenting symptom in ~70%; virtually pathognomonic when asymmetric
Rigidity	Often with cogwheeling (ratchety passive resistance)
Bradykinesia	Slowness of movement; patient may describe it as "weakness"

Other motor features: masked (expressionless) facies, micrographia, narrow shuffling gait, postural instability (late finding).

Non-motor features: dysphagia (objective prevalence up to 82%), aspiration (15–56% of patients), drooling, autonomic dysfunction, depression, hallucinations, and dementia in later stages. Death often results from aspiration pneumonia or trauma from falls.

Differential Diagnosis (Parkinsonism-Plus Syndromes)

Up to 20% of patients initially diagnosed with PD ultimately have an alternative diagnosis. Red flags suggesting a parkinsonism-plus syndrome:

Hallucinations or early dementia
Early postural instability or autonomic dysfunction
Paralysis of vertical gaze
Failure to respond to levodopa
Involuntary movements other than tremor

Key mimics:

Condition	Distinguishing Features
Progressive Supranuclear Palsy (PSP)	Vertical gaze palsy (especially downward), axial rigidity, poor levodopa response
Dementia with Lewy Bodies	Early cognitive impairment and hallucinations, rigidity > tremor
Multisystem Atrophy	Autonomic dysfunction (orthostatic hypotension), cerebellar signs, poor levodopa response
Vascular Parkinsonism	Step-wise progression, MRI multi-infarcts, lower-body predominance
Drug-induced Parkinsonism	History of dopamine blockers (neuroleptics, metoclopramide, amiodarone, valproic acid, lithium) — usually reversible

Treatment

Strategy

Therapy aims to:

Restore dopamine in the basal ganglia
Antagonize excess cholinergic activity

Drugs offer symptomatic relief only — none currently slow neurodegeneration.

Levodopa + Carbidopa (First-line)

Levodopa is the immediate precursor of dopamine and crosses the blood-brain barrier; dopamine itself does not
Carbidopa inhibits peripheral DOPA decarboxylase → reduces peripheral conversion of levodopa to dopamine, cutting the required levodopa dose by 4–5× and reducing peripheral side effects (nausea, vomiting, arrhythmias)
Effective for bradykinesia, rigidity, and tremor
Substantially reduces symptoms in ~2/3 of patients for the first few years; decline in response typically begins in the 3rd–5th year
"On-off" phenomenon: unpredictable motor fluctuations, not simply related to plasma levels

Adverse effects of levodopa:

Peripheral: nausea/vomiting (CTZ stimulation), orthostatic hypotension, tachycardia, dyskinesias
CNS: visual/auditory hallucinations, abnormal involuntary movements (dyskinesias) from dopamine overactivity
Urine/saliva may darken (melanin from catecholamine oxidation)

Key interactions:

Pyridoxine (B6) → increases peripheral levodopa breakdown → reduces efficacy
Non-selective MAOIs → contraindicated (risk of hypertensive crisis)

MAO-B Inhibitors

Drug	Notes
Selegiline	Selective MAO-B inhibitor; reduces dopamine metabolism; metabolized to amphetamine (risk of insomnia)
Rasagiline	5× more potent than selegiline; not metabolized to amphetamine
Safinamide	MAO-B inhibitor; adjunct to levodopa-carbidopa

All: avoid concurrent serotonergic agents (serotonin syndrome risk).

Dopamine Agonists

Used as monotherapy in early disease or adjuncts to levodopa. Help reduce motor fluctuations.

Anticholinergics

Reduce relative excess of ACh; useful particularly for tremor and rigidity.

COMT Inhibitors (e.g., entacapone, tolcapone)

Inhibit peripheral breakdown of levodopa → prolong its effect; adjuncts that reduce "wearing off."

Deep Brain Stimulation (DBS)

Electrodes implanted in the globus pallidus or subthalamic nucleus modulate basal ganglia circuitry, allowing significant reduction in levodopa dose in appropriate candidates.

Managing PD Psychosis

A therapeutic challenge: dopamine-enhancing treatments cause hallucinations, while dopamine blockers (antipsychotics) worsen motor symptoms.

Most antipsychotics are contraindicated in PD
Low-dose quetiapine or clozapine (weak D2 blockade) may be used cautiously
Pimavanserin (5-HT2A inverse agonist/antagonist) — approved specifically for PD psychosis; no direct dopamine antagonism, thus low risk of worsening the movement disorder

Disease Course

PD typically progresses over 10–15 years, eventually producing severe motor slowing approaching near-immobility. Early initiation of treatment is recommended when symptoms cause functional impairment.

Sources: Textbook of Family Medicine 9e; Robbins & Kumar Basic Pathology; Lippincott Illustrated Reviews: Pharmacology; Bradley and Daroff's Neurology in Clinical Practice

pyramidal role

Finding Sources

Reading File

Loading Image

Here is a comprehensive overview of the Pyramidal (Corticospinal) System — its anatomy, physiology, and clinical significance.

The Pyramidal System

Terminology

The term "pyramidal tract" is a near-synonym for the corticospinal tract. The name comes from the triangular-shaped medullary pyramids on the ventral surface of the medulla oblongata, where these fibers collect before crossing. The terminology is somewhat imprecise, as the medullary pyramids also include some reticulospinal and other brainstem pathway fibers — but in clinical practice, "pyramidal" refers to the corticospinal system.

Origin: Motor Cortex

The corticospinal tract does not arise solely from the primary motor cortex. Its origins are:

Source	Contribution
Primary motor cortex (Brodmann area 4, precentral gyrus)	~30–50%
Premotor & supplementary motor areas (area 6)	~30%
Somatosensory cortex (areas 3, 1, 2, 5, 7, posterior to central sulcus)	~30–40%

The cortical neurons contributing to this tract reside mainly in cortical layer 5. About 3% are giant Betz cells — the largest neurons in the human nervous system (~60 µm diameter), found exclusively in the primary motor cortex. Their axons conduct at ~70 m/s, the fastest of any corticospinal fibers. The total fiber count per tract exceeds 1 million.

Course of the Pyramidal Tract

Lateral corticospinal tract — upper motor neuron in precentral gyrus descending to pyramidal decussation and lower motor neuron in anterior horn

Step-by-step descent:

Corona radiata — axons from the motor cortex fan out into the cerebral white matter
Internal capsule (posterior limb) — fibers condense into a compact bundle; somatotopic organization is preserved:
- Face fibers → most anterior (genu)
- Arm fibers → mid-posterior limb
- Leg fibers → most posterior
- Lesions here often produce contralateral hemiplegia affecting face, arm, and leg together
Cerebral peduncles (basis pedunculi) — middle third carries corticospinal and corticobulbar fibers; face medial, leg lateral
Ventral pons — fibers scatter into fascicles as pontine nuclei and transverse fibers (destined for the cerebellum) interrupt them
Medullary pyramids — fibers reconverge on the ventral medulla surface, forming the visible pyramids
Pyramidal decussation (cervicomedullary junction, foramen magnum level):
- ~85% of fibers cross → enter lateral white matter of spinal cord → lateral corticospinal tract
- ~15% remain ipsilateral → anterior (ventral) corticospinal tract (most eventually cross in the cervical/upper thoracic cord; control bilateral postural movements)
Spinal cord — fibers descend somatotopically in the lateral column and synapse onto:
- Interneurons in the intermediate gray (mainly)
- Directly onto anterior horn cells (lower motor neurons) — particularly in cervical and lumbosacral enlargements controlling the hands and feet

Function

The pyramidal system is the primary pathway for voluntary, skilled, fine motor control, especially of the distal extremities (hands and fingers). Key functions:

Initiation and precise execution of voluntary movements
Speed and fractionation of finger movements
Modulation of spinal reflex circuits
Some corticospinal axons (from somatosensory cortex) regulate afferent sensory input (gate proprioceptive and tactile signals entering the dorsal horn)

Additional Fiber Pathways from Motor Cortex

Beyond the main corticospinal tract, the motor cortex also sends fibers to:

Caudate nucleus & putamen → basal ganglia circuits (postural control)
Red nucleus (midbrain) → rubrospinal tract
Reticular formation & vestibular nuclei → reticulospinal and vestibulospinal tracts
Pontine nuclei → cerebellum (corticopontocerebellar pathway)

Upper vs. Lower Motor Neuron

The pyramidal system is synonymous with the upper motor neuron (UMN) system.

Feature	UMN Lesion (Pyramidal)	LMN Lesion
Weakness	Yes (contralateral)	Yes (ipsilateral)
Tone	Increased (spasticity)	Decreased (flaccidity)
Reflexes	Hyperreflexia	Hyporeflexia / areflexia
Babinski sign	Positive (extensor plantar)	Absent
Atrophy	Minimal (disuse only)	Prominent (denervation)
Fasciculations	Absent	Present
Clonus	May be present	Absent

Clinical significance of lesion location:

Internal capsule (e.g., capsular stroke) → contralateral face + arm + leg hemiplegia
Cerebral peduncle → contralateral hemiplegia ± ipsilateral CN III palsy (Weber syndrome)
Ventral pons → contralateral hemiplegia ± ipsilateral CN VI palsy
Lateral spinal cord → ipsilateral UMN weakness below the level (tract already crossed), combined with Brown-Séquard features
Foramen magnum / upper cervical cord → may cause quadriparesis + lower cranial nerve signs

Why "Pyramidal" in Parkinson Disease Context?

In Parkinson disease, the extrapyramidal system (basal ganglia circuits) is primarily diseased — NOT the pyramidal tract. This is why PD produces:

Hypokinesia/bradykinesia (reduced movement initiation)
Rigidity (not spasticity)
Resting tremor
Normal or reduced reflexes (no Babinski sign)

This is the key distinguishing feature: pyramidal lesions → spasticity + hyperreflexia + Babinski; extrapyramidal (PD) → rigidity + bradykinesia, normal reflexes.

Sources: Neuroanatomy through Clinical Cases 3rd Ed.; Guyton and Hall Textbook of Medical Physiology; Bradley and Daroff's Neurology in Clinical Practice

This is a shared conversation. Sign in to Orris to start your own chat.